Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. RESULTS: At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02). CONCLUSIONS: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“alirocumab, a PCSK9 monoclonal antibody in clinical use (Robinson et al., 2015)”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Robinson et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Data from the GLAGOV, ODYSSEY COMBO I and ODYSSEY LONG TERM trials show greater efficacy of PCSK9 inhibitors in patients with prior CVD (or myocardial infarction) in terms of LDL-C and percent atheroma volume [86–88].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [270]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Items 501–600 of 1,019
Non-alcoholic fatty liver disease: a narrative review of genetics
Christopher, J., Zemin, Y., & Jiang, Z. G. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.32.20180045 · Cited by 50
Hong-mei, G., & Zhang, D. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150067 · Cited by 50
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
Filippatos, T. D., Kei, A. A., Rizos, C. V., & Elisaf, M. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417724868 · Cited by 48
Khoury, P. E., Elbitar, S., Ghaleb, Y., Khalil, Y. A., Varret, M., Boileau, C., & Abifadel, M. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0684-8 · Cited by 51
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer
Momtazi‐Borojeni, A. A., Nik, M. E., Jaafari, M. R., Banach, M., & Sahebkar, A. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.84732 · Cited by 46
Singh, G., Hussain, Y., Xu, Z., Sholle, E., Michalak, K., Dolan, K., Lee, B. C., van Rosendael, A. R., Fatima, Z., Peña, J. M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239934 · Cited by 51
Ferraz‐Amaro, I., Hernández-Hernández, V., Segura, B. T., Delgado-Frías, E., Macía-Díaz, M., Machado, J. D., & Díaz‐González, F. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0833-4627 · Cited by 47
“Similarly, serine protease proprotein convertase subtilisin kexin 9 (PCSK9), a key enzyme in the LDL cholesterol clearance pathway, has been also linked to cardiovascular events [18].”
BackgroundLow-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040943 · Cited by 51
“[77,78].”
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Stoekenbroek, R. M., Kastelein, J. J. P., & Huijgen, R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0503-4 · Cited by 49
“A prevalence of approximately 5 % of injection site reactions was reported by patients in the active treatment arms with evolocumab or alirocumab [21, 23].”
BackgroundInfluentialSelf-citationEmami, H., Takx, R. A. P., Mayrhofer, T., Janjua, S., Park, J., Pursnani, A. K., Tawakol, A. A., Lu, M. T., Ferencik, M., & Hoffmann, U. (2017) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2016.10.022 · Cited by 46
Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
Hines, D. M., Rane, P., Patel, J., Harrison, D. J., & Wade, R. L. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s180496 · Cited by 45
Lysosomal acid lipase deficiency – early diagnosis is the key
Strebinger, G., Müller, E., Feldman, A., & Aigner, E. S. (2019) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s201630 · Cited by 45
Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Zarić, B. L., Obradovic, M. M., Trpković, A., Banach, M., Mikhailidis, D. P., & Isenović, E. R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190903112146 · Cited by 46
Ray, K. K., Dhalwani, N. N., Sibartie, M., Bridges, I. M., Ebenbichler, C. F., Filardi, P. P., Villa, G., Vogt, A., & Bruckert, É. (2022) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcac009 · Cited by 47
Novel therapeutics in hypertriglyceridemia
Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44
Mefford, M. T., Rosenson, R. S., Cushman, M., Farkouh, M. E., McClure, L. A., Wadley, V. G., Irvin, M. R., Bittner, V., Safford, M. M., Somaratne, R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029785 · Cited by 44
Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study
Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy060 · Cited by 44
PCSK9 inhibitors: current status and emerging frontiers in lipid control
Agnello, F. G., Mauro, M. S., Rochira, C., Landolina, D., Finocchiaro, S., Greco, A., Ammirabile, N., Raffo, C., Mazzone, P. M., Spagnolo, M., et al. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2288169 · Cited by 45
CARDIOVASCULAR DISEASE, SIGNALING, GENE/CELL THERAPY AND ADVANCED NANOBIOMATERIALS
Erdil, N. (2024) · Advances in Biology & Earth Sciences · doi:10.62476/abes9s58 · Cited by 44
Rey, J., Poitiers, F., Paehler, T., Brunet, A., DiCioccio, A. T., Cannon, C. P., Surks, H. K., Pinquier, J., Hanotin, C., & Sasiela, W. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003323 · Cited by 45
The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
Hartiala, J., Schwartzman, W. S., Gabbay, J., Ghazalpour, A., Bennett, B. J., & Allayee, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0641-6 · Cited by 47
New treatment options for lipid-lowering therapy in subjects with type 2 diabetes
Scicali, R., Pino, A. D., Ferrara, V., Urbano, F., Piro, S., Rabuazzo, A. M., & Purrello, F. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1089-4 · Cited by 46
Feng, Q., Wei, W., Chung, C. P., Levinson, R. T., Sundermann, A. C., Mosley, J. D., Bastarache, L. A., Ferguson, J. F., Cox, N. J., Roden, D. M., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002642 · Cited by 46
Casula, M., Olmastroni, E., Boccalari, M. T., Tragni, E., Pirillo, A., & Catapano, A. L. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.021 · Cited by 46
Dyslipidemia and cardiovascular health in childhood nephrotic syndrome
Hari, P., Khandelwal, P., & Smoyer, W. E. (2019) · Pediatric Nephrology · doi:10.1007/s00467-019-04301-y · Cited by 55
New developments in proprotein convertase subtilisin–kexin 9's biology and clinical implications
Seidah, N. G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000295 · Cited by 43
Serban, M.-C., Banach, M., & Mikhailidis, D. P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1118055 · Cited by 44
“tive to diet.[78] The efficacy and safety of alirocumab in numerous clinical settings and patient groups were”
BackgroundNissen, S. E., Dent‐Acosta, R. E., Rosenson, R. S., Stroes, E., Sattar, N., Preiss, D., Mancini, G. B. J., Ballantyne, C. M., Catapano, A., Gouni‐Berthold, I., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22518 · Cited by 43
Self-citationLipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 46
Novel Therapeutic Targets for Managing Dyslipidemia
Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 44
Selker, H. P., Eichler, H., Stockbridge, N., McElwee, N. E., Dere, W. H., Cohen, T., Erban, J. K., Seyfert‐Margolis, V., Honig, P. K., Kaitin, K. I., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1347 · Cited by 46
Immunität und Entzündung bei Arteriosklerose
Wolf, D., & Ley, K. F. (2019) · Herz · doi:10.1007/s00059-019-4790-y · Cited by 48
Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
Momtazi‐Borojeni, A. A., Jaafari, M. R., Banach, M., Gorabi, A. M., Sahraei, H., & Sahebkar, A. (2021) · Vaccines · doi:10.3390/vaccines9070749 · Cited by 44
Pirillo, A., Catapano, A. L., & Norata, G. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00972-x · Cited by 46
Identification and treatment of the vulnerable coronary plaque
van Veelen, A., van der Sangen, N. M. R., Henriques, J. P. S., & Claessen, B. E. P. M. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2301039 · Cited by 48
PHARMACIST'S LETTER / PRESCRIBER'S LETTER
Symptoms, S. M., & Intolerance, M. S. (2015) · Cited by 43
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C. P., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 44
Wang, Q., Wang, Y., Lehto, K., Pedersen, N. L., Williams, D. M., & Hägg, S. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.007 · Cited by 43
Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
Azari, S., Rezapour, A., Omidi, N., Alipour, V., Behzadifar, M., Safari, H., Tajdini, M., & Bragazzi, N. L. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09874-2 · Cited by 44
Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial
Turan, T. N., Voeks, J. H., Chimowitz, M. I., Roldan, A., LeMatty, T., Haley, W. E., Lopes-Virella, M. F., Chaturvedi, S., Jones, M. R., Heck, D. V., et al. (2020) · Stroke · doi:10.1161/strokeaha.120.030730 · Cited by 43
Mukaz, D. K., Zakai, N. A., Cruz‐Flores, S., McCullough, L. D., & Cushman, M. (2020) · Stroke · doi:10.1161/strokeaha.120.030425 · Cited by 49
Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study
Gaudet, D., Lopez-Sendon, J. L., Averna, M. R., Bigot, G., Banach, M., Letierce, A., Loy, M., Samuel, R., Manvelian, G. Z., Batsu, I., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa097 · Cited by 42
Self-citationAlirocumab after acute coronary syndrome in patients with a history of heart failure
White, H. D., Schwartz, G. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Goodman, S. G., Jukema, J. W., Loy, M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab804 · Cited by 41
Self-citationInsight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
Gouni‐Berthold, I., Descamps, O. S., Fraass, U., Hartfield, E., Allcott, K., Dent, R. E., & März, W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13066 · Cited by 43
The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
Lambert, G. C., Thedrez, A., Croyal, M., Ramin‐Mangata, S., Couret, D., Diotel, N., Nobécourt, E., Krempf, M., LeBail, J. C., Poirier, B., et al. (2017) · Clinical Science · doi:10.1042/cs20160403 · Cited by 42
Self-citationFamilial hypercholesterolemia in Canada: Initial results from the FH Canada national registry
Brunham, L. R., Ruel, I. L., Khoury, É., Hegele, R. A., Couture, P., Bergeron, J., Baass, A. W., Dufour, R., Francis, G. A., Cermakova, L., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.040 · Cited by 43
Self-citationFang, C.-L., Luo, T., & Lin, L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.04 · Cited by 36
“Accordingly, due to dual mechanisms in lipids and inflammation, PCSK9 inhibitors had proved to be highly promising drugs bringing added cardiovascular benefit in ODYSSEY LONG TERM trial and FOURIER trial (7-9).”
BackgroundApoB in clinical care: Pro and Con
Sniderman, A. D., & Robinson, J. G. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.001 · Cited by 43
Self-citationGao, F., Wang, Z. J., Ma, X., Shen, H., Yang, L., & Zhou, Y. J. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01528-3 · Cited by 45
Non-stenotic Carotid Plaques in Embolic Stroke of Unknown Source
Tatuene, J. K., Nomani, A. Z., Falcione, S. R., Munsterman, D., Sykes, G. P., Joy, T., Spronk, E., Vargas, M. I., & Jickling, G. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.719329 · Cited by 41
Bae, K.-H., Kim, S. W., Choi, Y., Seo, J. B., Kim, N., Kim, C., Lee, W. K., Lee, S., Kim, J. G., Lee, I., et al. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.0081 · Cited by 42
PCSK9 inhibitors – past, present and future
Reiner, Ž. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1075506 · Cited by 41
Treatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
Veterans Health Administration
Skarl, S. (2016) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2016.1202021 · Cited by 40
Santos, R. D., Wiegman, A., Caprio, S., Cariou, B., Averna, M. R., Poulouin, Y., Scemama, M., Manvelian, G. Z., Garon, G., & Daniels, S. R. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2023.6477 · Cited by 47
Self-citationSecondary prevention after coronary artery bypass graft surgery: a primer
Kulik, A. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000331 · Cited by 42
Abtan, J., Bhatt, D. L., Elbez, Y., Sorbets, E., Eagle, K. A., Reid, C. M., Baumgärtner, I., Wu, D., Hanson, M. E., Hannachi, H., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22721 · Cited by 42
MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
Momtazi‐Borojeni, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8611-x · Cited by 43
“Preliminary findings from post-hoc or exploratory analysis of phase III trials with evolocumab and alirocumab provided encouraging evidence that the LDL-C reductions resulted in further reductions in CVD when added to existing statin with or without ezetimibe therapy [83, 84].”
BackgroundSattar, N. A., Toth, P. P., Blom, D. J., Koren, M. J., Soran, H., Uhart, M., Elliott, M., Cyrille, M., Somaratne, R. M., & Preiss, D. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.047 · Cited by 42
Self-citationLipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
Zheng-Lin, B., & Ortíz, A. (2018) · Drugs · doi:10.1007/s40265-017-0858-2 · Cited by 41
“Moreover, alirocumab and evolocumab also raised serum HDL-C by 5–10% [62, 63].”
BackgroundHippe, D. S., Phan, B. A. P., Sun, J., Isquith, D. A., O’Brien, K. D., Crouse, J. R., Anderson, T. J., Huston, J., Marcovina, S. M., Hatsukami, T. S., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310368 · Cited by 41
Cammisotto, V., Baratta, F., Simeone, P., Barale, C., Lupia, E., Galardo, G., Santilli, F., Russo, I., & Pignatelli, P. (2022) · Antioxidants · doi:10.3390/antiox11030569 · Cited by 42
“Their use reduces circulating LDL-c by about 40–65% when used on top of statins [16,17].”
BackgroundDeora, N., & Venkatraman, K. (2022) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2022.100675 · Cited by 41
Su, J., Xu, J., Yang, J., Yu, Q., Yang, S., Zhang, J., Yao, Q. Z., Zhu, Y., Luo, Y., Ji, L., et al. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0114-2 · Cited by 40
“Two recent studies demonstrated that alirocumab or evolocumab, when added to statin therapy, significantly reduced LDL-C levels and reduced the incidence of cardiovascular events [43, 44].”
BackgroundMcCormack, T., Dent, R., & Blagden, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12881 · Cited by 39
Fowler, A., Rompay, K. K. A. V., Sampson, M. L., Leo, J., Watanabe, J., Usachenko, J. L., Immareddy, R., Lovato, D. M., Schiller, J. T., Remaley, A. T., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00743-6 · Cited by 43
Elshazly, M. B., Nicholls, S. J., Nissen, S. E., John, J. S., Martin, S. S., Jones, S. R., Quispe, R., Stegman, B., Kapadia, S. R., Tuzcu, E. M., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.06.021 · Cited by 39
Kosmas, C. E., DeJesus, E., Morcelo, R., Garcia, F., Montan, P. D., & Guzman, E. (2017) · Drugs in Context · doi:10.7573/dic.212511 · Cited by 40
Ljungberg, J., Holmgren, A., Bergdahl, I. A., Hultdin, J., Norberg, M., Näslund, U., Johansson, B. H., & Söderberg, S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007160 · Cited by 39
Chan, D. C., Watts, G. F., Somaratne, R., Wasserman, S. M., Scott, R., & Barrett, P. H. R. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310882 · Cited by 35
Obesity-Related Asthma: Immune Regulation and Potential Targeted Therapies
Yuan, Y., Ran, N., Xiong, L., Wang, G., Guan, X., Wang, Z., Guo, Y., Pang, Z., Fang, K., Lu, J., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/1943497 · Cited by 43
Dyslipidemias in clinical practice
Cabezas, M. C., Burggraaf, B., & Klop, B. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.09.010 · Cited by 45
Tan, J., Hu, M., Yang, Y., & Yang, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.798334 · Cited by 66
Laufs, U., Scharnagl, H., & März, W. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000236 · Cited by 43
The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress
Bale, B. F., Doneen, A. L., Leimgruber, P. P., & Vigerust, D. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1042729 · Cited by 40
Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry
Galema‐Boers, A. M. H., Mulder, J. W. C. M., Steward, K., & van Lennep, J. E. R. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.013 · Cited by 39
The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis
Yu, M., Tsai, S., & Kuo, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061260 · Cited by 39
Musunuru, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.002 · Cited by 44
PCSK9 Inhibitors and Cardiovascular Events
Sabatine, M. S., Wasserman, S. M., & Stein, E. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508222 · Cited by 39
PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway
Liu, L.-S., Bai, X.-Q., Gao, Y., Wu, Q., Ren, Z., Li, Q., Pan, L.-H., He, N.-Y., Peng, J., & Tang, Z.-H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161136 · Cited by 38
Tănase, D. M., Valasciuc, E., Gosav, E. M., Floria, M., Costea, C. F., Dima, N., Tudorancea, I., Maranducă, M. A., & Șerban, I. L. (2022) · Cells · doi:10.3390/cells11172663 · Cited by 39
Fixed Combination for the Treatment of Dyslipidaemia
Ferri, N., Ruscica, M., Santos, R. D., & Corsini, A. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01142-x · Cited by 40
“This association is maintained up to very low levels of LDL-C [6, 7].”
BackgroundGalema‐Boers, A. M. H., Lenzen, M. J., Sijbrands, E. J. G., & van Lennep, J. E. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.014 · Cited by 41
Choi, H., Hwang, J., Nam, T. G., Kim, S. H., Min, D., Park, S. W., & Chung, M. (2017) · Food & Function · doi:10.1039/c7fo00562h · Cited by 39
Stigmasterol accumulation causes cardiac injury and promotes mortality
Tao, C., Shkumatov, A. A., Alexander, S. T., Ason, B. L., & Zhou, M. (2019) · Communications Biology · doi:10.1038/s42003-018-0245-x · Cited by 38
Collet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 44
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 67
Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study
Goldman, A., Raschi, E., Cukierman‐Yaffe, T., Dankner, R. S., Shouval, R., Shechter, M., Ben‐Zvi, I., Gerstein, H. C., & Maor, E. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab209 · Cited by 38
Bruikman, C. S., Stoekenbroek, R. M., Hovingh, G. K., & Kastelein, J. J. P. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.010 · Cited by 45
Self-citationMK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
Burnett, J. R., & Hooper, A. J. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2267972 · Cited by 38
“Two human mAbs against PCSK9, namely alirocumab (Sanofi/Regeneron) and evolocumab (Amgen) [9,10], have been in clinical use since 2015 and in randomized controlled trials have been shown to potently lower LDL-cholesterol and reduce cardiovascular events in patients with ASCVD when given…”
BackgroundSex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors
Rivera, F. B., Cha, S. W., Aparece, J. P., Rocimo, A. M. R., Ong, B., Golbin, J. M., Alfonso, P. G., Enkhmaa, B., Khan, S. U., Cainzos‐Achirica, M., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100669 · Cited by 37
Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 42
“[93,100] Therefore, for diabetic patients with ASCVD and high baseline LDL-C levels (LDL-C ≥ 4.9 mmol/L for patients not using statins and LDL-C ≥ 2.6 mmol/L for patients using statins), or when it is expected that combining statins and cholesterol absorption inhibitors will be difficult to…”
InfluentialDu, H., Li, X., Su, N., Li, L., Hao, X., Gao, H., Kwong, J. S.-W., Vandvik, P. O., Yang, X., Németh, I., et al. (2019) · Heart · doi:10.1136/heartjnl-2019-314763 · Cited by 42
Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease
Ali, S., Dave, N., Virani, S. S., & Navaneethan, S. D. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0794-6 · Cited by 40
Antibody engineering and its therapeutic applications
Kandari, D., & Bhatnagar, R. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1960986 · Cited by 42
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction
Mátyás, C., Trojnár, E., Zhao, S., Arif, M., Mukhopadhyay, P., Kovács, A. D., Fábián, A., Tokodi, M., Bagyura, Z., Merkely, B. P., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.06.005 · Cited by 37
Alirocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305354 · Cited by 38
“Drug summary Drug name: Alirocumab Phase: Launched Indications: Hypercholesterolemia Mechanism of action: PCSK9 inhibition Route of administration: Subcutaneous injection Pivotal trial(s): ODYSSEY FH1 (NCT01623115) [39] ODYSSEY FH2 (NCT01709500) [39] ODYSSEY HIGH FH (NCT01617655) [40] ODYSSEY COMBO I (NCT01644175) [42…”
BackgroundResultInfluentialZafrir, B., & Jubran, A. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12439 · Cited by 42
Metadata
- Authors
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., & Kastelein, J. J. P.
- Affiliations
- University of Iowa (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Lille (FR)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Jacksonville Center for Clinical Research (US)
- Westside Medical Associates of Los Angeles (US)
- Sanofi (France) (FR)
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1489-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001328643
- Semantic Scholar
- 942bcfdc93b04ccb90a2d3e1df4c7950a45e92c2
- Cited by
- 2,296
- References
- 35
- Citations by year
- 2026: 67 · 2025: 103 · 2024: 150 · 2023: 141 · 2022: 134 · 2021: 159 · 2020: 165 · 2019: 226 · 2018: 251 · 2017: 339 · 2016: 369 · 2015: 183
- FWCI
- 383.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- alirocumab, PCSK9 inhibition, LDL cholesterol lowering, statin therapy, major adverse cardiovascular events, cardiovascular risk reduction, monoclonal antibodies, injection site reactions, high-risk patients, lipid-lowering therapy
- MeSH terms
- Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.